Research map: Regulatory Alignment on Surrogate Endpoints for Slowly Progressive Ultra-Rare Neurological Diseases: Bridging the Gap Between Biomarker Science and Global Regulatory Acceptance

Back to the article

Papers in this map

  1. Surrogate End Points in Clinical Trials: Are We Being Misled? · Thomas R. Fleming · 1996 · 1654 citations · Cited by this paper
  2. Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA Perspective · 2026 · Related
  3. Clinical research for rare disease: Opportunities, challenges, and solutions · Robert C. Griggs · 2008 · 414 citations · Cited by this paper
  4. Impacts of Random and Fixed Effect Models on Type I and Type II Errors in Bioequivalence Hypotheses in Crossover Trial Designs: A Comprehensive Simulation Study · 2026 · Related
  5. Estimating the number of diseases – the concept of rare, ultra-rare, and hyper-rare · C. I. Edvard Smith · 2022 · 104 citations · Cited by this paper
  6. Trends and Regulatory Insights on Illicit Pharmaceutical and Cosmetic Imports: Evidence from Malaysia’s Operation Pangea 2020–2023 · 2026 · Related
  7. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen · Kelly A. Rich · 2021 · 34 citations · Cited by this paper
  8. The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA · 2026 · Related
  9. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen · Gigyo Seo · 2023 · 16 citations · Cited by this paper
  10. How Digital Health Technologies have been Used to Support Regulatory Drug Approval · 2026 · Related
  11. Neurofilament light chain and profilin‐1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen · Giulia Musso · 2024 · 11 citations · Cited by this paper
  12. Feasibility of a Monthly Morphine Milligram Equivalent Metric for Opioid Surveillance Using the National Claims Database of Japan: A Repeated Cross-Sectional Study in a Low-Consumption Setting · 2026 · Related
  13. Biomarkers for gene therapy clinical trials of lysosomal storage disorders · Alessandro Rossi · 2024 · 8 citations · Cited by this paper
  14. Measuring Centralized Patient Outreach Recruitment Strategies and their Costs in Clinical Trials · 2026 · Related
  15. Proportion of treatment effect explained: An overview of interpretations · Florian Stijven · 2024 · 6 citations · Cited by this paper
  16. Arbitrated Indirect Treatment Comparisons · 2026 · Related
  17. Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022 · Xiaofang Zhang · 2024 · 6 citations · Cited by this paper
  18. Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now? · 2026 · Related
  19. Surrogate Biomarkers in Gene Therapy for Orphan Diseases: Validation, Application, and Regulatory Aspects · Aysilu I. Mullagulova · 2025 · 5 citations · Cited by this paper
  20. Accelerating Global Access for Indication Extension Through Regulatory Reliance Pilot: The First Indication Extension Pilot in Oncology · 2026 · Related
  21. Surrogate Endpoints in Regulatory Decision‐Making · Linda B.J. Jeng · 2025 · 5 citations · Cited by this paper
  22. Pivotal trial characteristics and types of endpoints used to support Food and Drug Administration rare disease drug approvals between 2013 and 2022 · Kyungwan Hong · 2025 · 3 citations · Cited by this paper
  23. Overview of Orphan Medicines in European Union: An Analysis of Regulatory and Technical–Scientific Aspects · Greta Santi Laurini · 2025 · 2 citations · Cited by this paper
  24. Insights on Clinical Development of Cell and Gene Therapy for Rare Diseases—by DahShu Innovative Design Scientific Working Group (IDSWG) · Chenkun Wang · 2025 · 2 citations · Cited by this paper
  25. Accelerated approvals in oncology: Trial design strategies and insights driving successful regulatory outcomes across three decades · Rohini Sharma · 2025 · 2 citations · Cited by this paper
  26. Impact of China’s Drug Review and Approval System Reform on Pediatric Drugs: an Analysis Based on Registration Data from 2015 to 2024 · Tao Yang · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)